The endogenous selective estrogen receptor modulator 27-hydroxycholesterol is a negative regulator of bone homeostasis

Endocrinology

Volumn 151, Issue 8, 2010, Pages 3675-3685

  DuSell, Carolyn D ^a   Nelson, Erik R ^a   Wang, Xiaojuan ^a   Abdo, Jennifer ^a   Mödder, Ulrike I ^b   Umetani, Michihisa ^c   Gesty Palmer, Diane ^a   Javitt, Norman B ^d   Khosla, Sundeep ^b   McDonnell, Donald P ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

26 HYDROXYCHOLESTEROL; ALKALINE PHOSPHATASE BONE ISOENZYME; ESTROGEN RECEPTOR; FULVESTRANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE HOMEOSTASIS; BONE METABOLISM; BONE STRUCTURE; CONTROLLED STUDY; DISEASE EXACERBATION; ENZYME ACTIVITY; ESTROGEN ACTIVITY; ESTROGEN BLOOD LEVEL; FRAGILITY FRACTURE; HORMONAL REGULATION; MOUSE; NONHUMAN; OSSIFICATION; OSTEOCLASTOGENESIS; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; TRABECULAR BONE;

ANIMALS; BONE AND BONES; BONE DENSITY; BONE RESORPTION; CYTOCHROME P-450 CYP27A1; ESTRADIOL; FEMALE; HOMEOSTASIS; HYDROXYCHOLESTEROLS; MICE; MICE, KNOCKOUT; OSTEOBLASTS; OSTEOGENESIS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; STEROID HYDROXYLASES;

EID: 77954892925     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2010-0080     Document Type: Article

References (41)

1. Björkhem I, Cedazo-Minguez A, Leoni V, Meaney S 2009 Oxysterols and neurodegenerative diseases. Mol Aspects Med 30:171-179
2. Björkhem I, Andersson O, Diczfalusy U, Sevastik B, Xiu RJ, Duan C, Lund E 1994 Atherosclerosis and sterol 27-hydroxylase: evidence for a role of this enzyme in elimination of cholesterol from human macrophages. Proc Natl Acad Sci USA 91:8592-8596 (Pubitemid 24273710)
3. Olkkonen VM, Lehto M 2004 Oxysterols and oxysterol binding proteins: role in lipid metabolism and atherosclerosis. Ann Med 36:562-572 (Pubitemid 40051433)
4. Javitt NB 2002 25R,26-Hydroxycholesterol revisited: synthesis, metabolism, and biologic roles. J Lipid Res 43:665-670
5. Brown AJ, Jessup W 1999 Oxysterols and atherosclerosis. Atherosclerosis 142:1-28
6. DuSell CD, Umetani M, Shaul PW, Mangelsdorf DJ, McDonnell DP 2008 27-Hydroxycholesterol is an endogenous selective estrogen receptor modulator. Mol Endocrinol 22:65-77
7. Umetani M, Domoto H, Gormley AK, Yuhanna IS, Cummins CL, Javitt NB, Korach KS, Shaul PW, Mangelsdorf DJ 2007 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat Med 13:1185-1192 (Pubitemid 47530633)
8. Kim WS, Chan SL, Hill AF, Guillemin GJ, Garner B 2009 Impact of 27-hydroxycholesterol on amyloid-β peptide production and ATP-binding cassette transporter expression in primary human neurons. J Alzheimers Dis 16:121-131
9. DuSell CD, McDonnell DP 2008 27-Hydroxycholesterol: a potential endogenous regulator of estrogen receptor signaling. Trends Pharmacol Sci 29:510-514
10. Riggs BL, Khosla S, Melton 3rd LJ 1998 A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 13:763-773 (Pubitemid 28224192)
11. Manolagas SC 2000 Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21:115-137
12. Kalu DN, Salerno E, Liu CC, Ferarro F, Arjmandi BN, Salih MA 1993 Ovariectomy-induced bone loss and the hematopoietic system. Bone Miner 23:145-161 (Pubitemid 24028381)
13. García Palacios V, Robinson LJ, Borysenko CW, Lehmann T, Kalla SE, Blair HC 2005 Negative regulation of RANKL-induced osteoclastic differentiation in RAW264.7 cells by estrogen and phytoestrogens. J Biol Chem 280:13720-13727 (Pubitemid 40517267)
14. Krum SA, Miranda-Carboni GA, Hauschka PV, Carroll JS, Lane TF, Freedman LP, Brown M 2008 Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO J 27:535-545 (Pubitemid 351225684)
15. Kearns AE, Khosla S, Kostenuik PJ 2008 Receptor activator of nuclear factor κB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 29:155-192 (Pubitemid 351519689)
16. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL 1999 Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 140:4367-4370 (Pubitemid 30647136)
17. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ 1997 Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309-319
18. Lupattelli G, Scarponi AM, Vaudo G, Siepi D, Roscini AR, Gemelli F, Pirro M, Latini RA, Sinzinger H, Marchesi S, Mannarino E 2004 Simvastatin increases bone mineral density in hypercholesterolemic postmenopausal women. Metabolism 53:744-748
19. Rosenson RS, Tangney CC, Langman CB, Parker TS, Levine DM, Gordon BR 2005 Short-term reduction in bone markers with highdose simvastatin. Osteoporos Int 16:1272-1276
20. Sennerby U, Melhus H, Gedeborg R, Byberg L, Garmo H, Ahlbom A, Pedersen NL, Michaëlsson K 2009 Cardiovascular diseases and risk of hip fracture. JAMA 302:1666-1673
21. Browner WS, Seeley DG, Vogt TM, Cummings SR 1991 Nontrauma mortality in elderly women with low bone mineral density. Study of Osteoporotic Fractures Research Group. Lancet 338:355-358
22. von der Recke P, Hansen MA, Hassager C 1999 The association between low bone mass at the menopause and cardiovascular mortality. Am J Med 106:273-278
23. Keren Z, Falik-Zaccai TC 2009 Cerebrotendinous xanthomatosis (CTX): a treatable lipid storage disease. Pediatr Endocrinol Rev 7:6-11
24. Gesty-Palmer D, Flannery P, Yuan L, Corsino L, Spurney R, Lefkowitz RJ, Luttrell LM 2009 A β-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. Sci Transl Med 1:1ra1
25. Berginer VM, Shany S, Alkalay D, Berginer J, Dekel S, Salen G, Tint GS, Gazit D 1993 Osteoporosis and increased bone fractures in cerebrotendinous xanthomatosis. Metabolism 42:69-74
26. Federico A, Dotti MT, Loré F, Nuti R 1993 Cerebrotendinous xanthomatosis: pathophysiological study on bone metabolism. J Neurol Sci 115:67-70
27. Rosen H, Reshef A, Maeda N, Lippoldt A, Shpizen S, Triger L, Eggertsen G, Björkhem I, Leitersdorf E 1998 Markedly reduced bile acid synthesis but maintained levels of cholesterol and vitamin D metabolites in mice with disrupted sterol 27-hydroxylase gene. J Biol Chem 273:14805-14812
28. Schüle R, Siddique T, Deng HX, Yang Y, Donkervoort S, Hansson M, Madrid RE, Siddique N, Schöls L, Björkhem I 2010 Marked accumulation of 27-hydroxycholesterol in SPG5 patients with hereditary spastic paresis. J Lipid Res 51:819-823
29. Hirayama T, Mizokami Y, Honda A, Homma Y, Ikegami T, Saito Y, Miyazaki T, Matsuzaki Y 2009 Serum concentration of 27-hydroxycholesterol predicts the effects of high-cholesterol diet on plasma LDL cholesterol level. Hepatol Res 39:149-156
30. Lee CY, Huang SH, Jenner AM, Halliwell B 2008 Measurement of F2-isoprostanes, hydroxyeicosatetraenoic products, and oxysterols from a single plasma sample. Free Radic Biol Med 44:1314-1322
31. Zallone A 2006 Direct and indirect estrogen actions on osteoblasts and osteoclasts. Ann NY Acad Sci 1068:173-179 (Pubitemid 43824147)
32. Smith EP, Specker B, Bachrach BE, Kimbro KS, Li XJ, Young MF, Fedarko NS, Abuzzahab MJ, Frank GR, Cohen RM, Lubahn DB, Korach KS 2008 Impact on bone of an estrogen receptor-α gene loss of function mutation. J Clin Endocrinol Metab 93:3088-3096
33. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S 1996 Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14:78-84 (Pubitemid 26022463)
34. Doran PM, Riggs BL, Atkinson EJ, Khosla S 2001 Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men. J Bone Miner Res 16:2118-2125 (Pubitemid 32995404)
35. Practice Committee of American Society for Reproductive Medicine 2008 Estrogen and progestogen therapy in postmenopausal women. Fertil Steril 90(5 Suppl):S88-S102
36. Martin TJ, Gaddy D 2006 Bone loss goes beyond estrogen. NatMed 12:612-613 (Pubitemid 43869939)
37. Lindberg MK, Weihua Z, Andersson N, Movérare S, Gao H, Vidal O, Erlandsson M, Windahl S, Andersson G, Lubahn DB, Carlsten H, Dahlman-Wright K, Gustafsson JA, Ohlsson C 2002 Estrogen receptor specificity for the effects of estrogen in ovariectomized mice. J Endocrinol 174:167-178
38. Syed FA, Mödder UI, Fraser DG, Spelsberg TC, Rosen CJ, Krust A, Chambon P, Jameson JL, Khosla S 2005 Skeletal effects of estrogen are mediated by opposing actions of classical and nonclassical estrogen receptor pathways. J Bone Miner Res 20:1992-2001
39. Robertson KM, Norgård M, Windahl SH, Hultenby K, Ohlsson C, Andersson G, Gustafsson JA 2006 Cholesterol-sensing receptors, liver X receptor α and β, have novel and distinct roles in osteoclast differentiation and activation. J Bone Miner Res 21:1276-1287
40. Fu X, Menke JG, Chen Y, Zhou G, MacNaul KL, Wright SD, Sparrow CP, Lund EG 2001 27-Hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J Biol Chem 276:38378-38387
41. Song C, Liao S 2000 Cholestenoic acid is a naturally occurring ligand for liver X receptor α. Endocrinology 141:4180-4184